Abstract 245P
Background
Cervical cancer ranked second on women in Indonesia with 23.4/100,000 population incidence and 13.9/100,000 population mortality, emphasizing the importance of its screening and prevention. Indonesian government have applied cancer “see and treat” method with visual inspection using acetic acid (VIA) followed by cryotherapy procedure, but the number of women complying with the program were only 5% despite 80% target in 2013. This study aimed to explore factors influencing women with VIA positive result’s likelihood to receive cryotherapy.
Methods
Our cross-sectional study observed “see and treat” program at Temanggung District Health Office, Central Java, Indonesia, between March 29 and April 31, 2018. We used simple random sampling technique to select 356 VIA possitive women aged 30-50 years and collected data on whether they underwent cryotherapy, their demographic profile, education, knowledge and awareness about cryotherapy, and family support using structured questionnaire. Data were analyzed with chi square analysis on STATA software.
Results
In our study, 217 women (60.69%) received cryotherapy, while 139 women (39.04%) did not. Among all variables analysed, factors affecting subjects’ likelihood to underwent cryotherapy are knowledge about cryotherapy itself (PR = 0.776, 95%CI=0.660-0.913, p = 0.003), residence distance (PR = 0.795, 95%CI=0.650-0.971, p = 0.016), permission from family (PR = 0.675, 95%CI=0.556-0.820, p = 0.018), and accompaniment by their family (PR = 0.824, 95%CI=0.700-0.970, p = 0.026). Age, marital status, occupation, and education background did not show significant correlation with women’s decision to receive cryotherapy.
Conclusions
Our study showed that more individuals with VIA positive results were willing to receive cryotherapy as an effort to prevent cervical cancer. However, our study also showed knowledge about cryotherapy, residence distance, family permission and family accompaniment as factors lowering VIA possitive women’s likelihood to receive cryotherapy. Because this study is only limited on Temanggung population, further study is needed to explore larger population and other factors that might also influence this behavior.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ethics Committee, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada.
Funding
Board for Development and Empowerment Human Resources of Health, Ministry of Health Republic of Indonesia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract